Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Bearish 🐻 | Bullish 🐮 | It’s Complicated 😵‍💫

Here are the Stocktwits Top 25 Lists for this week:

ChatGPT is a superpower if you know how to use it correctly.

Discover how HubSpot's guide to AI can elevate both your productivity and creativity to get more things done.

Learn to automate tasks, enhance decision-making, and foster innovation with the power of AI.

Download the free guide

The Russell 2000 momentum board split between fresh analyst-backed entrants and biotech names carrying very specific data clocks.

$ERAS ( ▲ 3.69% ) : Erasca, up six spots to No. 7: Shares added 3.7% this week as traders positioned for updated ERAS-0015 monotherapy data with more patients and longer follow-up at November’s oncology symposium. Risk: The pancreatic-cancer program remains in Phase 1, making response durability and safety the binary test.

$PENG ( ▲ 6.58% ) : Penguin Solutions, new at No. 14: Penguin gained 6.6% this week after an earnings beat, stronger fiscal 2027 guidance, and a Bank of America Buy initiation with a $100 target. Risk: That target assumes above-consensus earnings, leaving little room for delayed AI deployments or softer memory demand.

$PBF ( ▼ 5.68% ) : PBF Energy, new at No. 23: PBF entered after analysts lifted targets, including Goldman Sachs to $91 from $81, as tight fuel markets supported refiners. Risk: A 10% owner sold $10.1M near the current price, and Oct. 29 earnings must defend refinery margins.

$SLS ( ▲ 3.46% ) : SELLAS Life Sciences, new at No. 24: SELLAS gained 3.5% as its REGAL leukemia trial approached the 80th event required for final Phase 3 analysis, with SLS009 data also due this quarter. Risk: SELLAS remains blinded, and both programs face binary clinical readouts with uncertain timing.

$TWST ( ▲ 5.08% ) : Twist Bioscience, down two spots to No. 4: Twist fell 15.3% this week after Jefferies initiated coverage at Hold with a $150 target and ARK continued reducing its position. Risk: Shares remain above that target, while recent insider sales add another source of supply.

Next week’s swing factor: Wednesday’s CPI and Thursday’s PPI and retail-sales report will reset rate expectations across long-duration biotech and unprofitable technology names.

Want to see some change? Respond to this email and reach me, Kevin Travers, with feedback. Follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋